| Document Date: 2012-12-13 18:06:00
Open Document File Size: 169,38 KBShare Result on Facebook
City Kingston / Toronto / / Company CTG IND. / Grade AE / Astex Pharmaceuticals / / Country Canada / / Event FDA Phase / / Facility Stable Disease / B complex / Princess Margaret Hospital / / MedicalCondition symptomatic cardiac dysfunction / ovarian cancer / measurable disease / cancer / refractory solid tumours / lymphoma / NSCLC / colorectal cancer / mantle cell lymphoma / Esophagus Melanoma Breast Thyroid Sarcoma / pulmonary function / human tumor / solid tumors / neutropenia / nausea / tumour / metastatic solid tumors OR / Thrombocytopenia / muscle weakness / mucositis / metastatic disease / HCT116 colon cancer / radiologically documented disease / vomiting / fatigue / febrile neutropenia / non-Hodgkin lymphoma refractory / Lymphopenia / stable disease / infection / renal failure / renal dysfunction / hypokalemia / rash / No untreated CNS metastases / Primary tumor / / MedicalTreatment chemotherapy / / Organization Princess Margaret Hospital / Adverse Event AT7519M Administration / L. Seymour Juravinski Cancer Centre / / Person A. Jarvi / V / / Position NSCLC Colon Head / / Product CDK2 / AT7519M / RP2D / / ProvinceOrState Ontario / / Technology Pharmacokinetics / X-ray / chemotherapy / drug design / apoptosis / /
SocialTag |
ABSTRACT # 491 NCIC CTG IND.177: Phase I Study of AT7519M Given as a Short Infusion Twice Weekly S. J. Hotte, E. X. Chen, L. McIntosh, H. Hirte, S. Turner, A. Jarvi, V. Lock, L. Seymour